Long-Term Clinical Outcomes of Biodegradable-Polymer Drug-Eluting Stents Versus Second-Generation Durable-Polymer Drug-Eluting Stents for ST-Segment Elevation Myocardial Infarction

• Published in: Cardiovascular revascularization medicine Vol. 35; pp. 98 - 103
• Main Authors: Sim, Hui Wen, Thong, Elizabeth H., Djohan, Andie H., Chen, Jason Z., Ser, Joon Sin, Loh, Poay Huan, Lee, Chi-Hang, Chan, Mark Y., Low, Adrian F., Tay, Edgar L., Chan, Koo Hui, Tan, Huay Cheem, Loh, Joshua P.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2022
• Subjects: Absorbable Implants; Biodegradable polymer; Drug eluting stent; Drug-Eluting Stents; Durable polymer; Humans; Myocardial Infarction - etiology; Myocardial Infarction - therapy; Percutaneous Coronary Intervention - adverse effects; Polymers; Prosthesis Design; ST Elevation Myocardial Infarction - diagnostic imaging; ST Elevation Myocardial Infarction - etiology; ST Elevation Myocardial Infarction - therapy; STEMI; Treatment Outcome; Durable polymer; STEMI; Biodegradable polymer; Drug eluting stent
• ISSN: 1553-8389; 1878-0938
• DOI: 10.1016/j.carrev.2021.04.014

Biodegradable polymer drug eluting stents (BP-DES) may offer the advantage of vascular healing in ST-segment elevation myocardial infarction (STEMI). Long-term outcome data comparing BP-DES and second-generation durable polymer drug eluting stents (DP-DES) in STEMI is lacking. This study aims to compare the long-term clinical outcomes of BP-DES versus second-generation DP-DES in STEMI. This is an observational study of consecutive patients with STEMI who received either BP-DES (n = 854) or DP-DES (n = 708) during primary percutaneous coronary intervention (PCI) from 1st February 2007 to 31st December 2016. The primary outcome was target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction (MI), and target lesion revascularization with follow up till 30th November 2019. The baseline demographics, lesion and procedural characteristic were similar between the two groups except for more prior MI and chronic obstructive pulmonary disease in the BP-DES group. At a median follow up of 4.2 years (interquartile range: 2.6–6.2 years), the incidence of TLF was similar between BP-DES and DP-DES (adjusted hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.70–1.26). Likewise, incidence of major adverse cardiovascular events (MACE: all-cause death, any MI or target vessel revascularization) and definite stent thrombosis were similar in both groups (MACE: adjusted HR 1.04, 95% CI 0.82–1.32; definite stent thrombosis: adjusted HR 1.06, 95% CI 0.31–3.64). Among patients with STEMI who underwent primary PCI, BP-DES and DP-DES implantation was associated with similar long-term clinical outcomes. •There was no difference in the incidence of TLF and MACE between BP-DES and DP-DES in STEMI.•There was no difference in the incidence of ST between BP-DES and DP-DES in STEMI.•TLF in both BP-DES and DP-DES groups were predominantly driven by cardiac deaths.